Purpose. To recommend a suitable disease-specific quality of life (QOL) instrument for use in intermittent claudication (IC) based on validity and responsiveness. Methods. Seventy claudicants completed two generic (SF36 and EUROQOL) and three disease-specific (CLAUS, VASCUQOL and SIP IC ) QOL instruments prior to and 6 months after treatment (angioplasty or conservative therapy). Ankle brachial pressure indices and treadmill walking distances were measured at each assessment and International Society of Cardiovascular Surgery (ISCVS) recommended outcome measures were used to stratify the results. Construct and convergent-divergent validity was assessed for the three disease-specific QOL instruments. Responsiveness was assessed using effect sizes (effect size O0.5 is clinically significant). Results. All clinical indicators improved significantly following treatment. All five domains of CLAUS, the VASCUQOL and SIP IC showed highly significant spearman correlation with intermittent claudication distance (ICD) and maximum walking distance (MWD) (0.267-0.697, pZ0.01), suggesting good construct validity. There was greater correlation between like domains of CLAUS and SF36 than non-like domains suggesting good convergent-divergent validity. Pain domain of CLAUS and VASCUQOL could detect mild clinical improvement significantly (effect sizes 0.55 and 0.67). Pain and everyday life domain of CLAUS and the VASCUQOL could detect moderate clinical improvement significantly (effect sizes 0.7, 0.74 and 0.56, respectively). Conclusion. The three disease-specific QOL instruments (CLAUS, VASCUQOL, SIP IC ) showed a high degree of construct and convergent-divergent validity. Amongst the three disease-specific QOL instruments, the VASCUQOL was most responsive and we would recommend its use in clinical practice.
Introduction
Intermittent claudication (IC) is a common condition, 1 which significantly impairs quality of life (QOL). Claudicants are limited not only in their walking capacity and physical activity, but also demonstrate substantial impairment in other QOL domains including social functioning, emotional and mental health. 2 Conservative management, exercise therapy, interventional radiology and surgery have all been used in the treatment of IC with the primary aim of reversing this QOL impairment. However, the most appropriate method of QOL analysis is disputed.
QOL may be analyzed using generic or diseasespecific instruments, with the later being more able to detect small changes. The aim of this study was to assess the validity and responsiveness of three commonly utilised disease-specific QOL instruments for IC, and make recommendations regarding standardisation of disease-specific QOL analysis in these patients.
Methods
A prospective study was conducted following ethics committee approval. Seventy ISCVS category II claudicants (38 men, median age 70 years) with lifestyle limiting claudication were recruited into the study over 1 year. Twenty-seven patients were current smokers (38%) and 14 were diabetics (20%). Thirty patients had bilateral claudication symptoms and in these patients the more symptomatic side or with equal symptoms, the side with the lower ankle brachial pressure index (ABPI) was considered for analysis. Forty-seven patients underwent percutaneous transluminal angioplasty (PTA) and 23 patients had conservative medical therapy (CMT). Patients were assessed prior to treatment and at 6 months after treatment. At each assessment patients' clinical indicators of lower limb ischaemia and QOL (generic and disease-specific) were analysed. Two generic questionnaires and three disease-specific questionnaires were used to analyse QOL. To achieve completion of questionnaires and avoid automatic patient responses, the order in which the questionnaires were presented to patients was varied and the questionnaires were checked for omission following self-completion by the patients.
Clinical indicators of lower limb ischaemia
The clinical indicators of lower limb ischaemia included were ankle brachial pressure index at rest (ABPI-R) and post-exercise (ABPI-PE) and walking distances-intermittent claudication distance (ICD) and maximum walking distance (MWD)-using a standard treadmill test (10 degree inclination at a constant speed of 2.5 km/h). The patients had no treadmill training prior to walking distance measurement. Since, this policy was followed throughout the study and for all patients, any effect of training (or lack of) should be uniform across the study. The outcome following treatment was also assessed using the International Society of Cardio Vascular Surgery (ISCVS) suggested outcome criteria (Table 1) .
Generic QOL instruments
Generic instruments included were the SF36 and the EUROQOL. The SF36 has 36 items or questions and records QOL over eight distinct dimensions or domains-physical function, role physical, bodily pain, general health, vitality, social function, role emotional and mental health. 3 The highest score for each domain is 100 (best QOL) and the lowest score is 0 (worst QOL). The SF36 is a popular and widely used QOL instruments in patients with peripheral vascular disease. The EUROQOL is administered in two parts. The first is a simple generic measure consisting of five questions, each with three possible responses. This part of the questionnaire is used to describe a brief health profile over five dimensions: mobility, self-care, usual activities, pain/discomfort and anxietydepression. The responses are also analysed using a time trade off (TTO) matrix to calculate a single health index called TTO index. The second part of the EUROQOL is a visual rating scale from 0 (worst imaginable health state) to 100 (best imaginable health state). This is read off directly as the visual analogue score (VAS). The EUROQOL thus produces a brief health profile and two health indices the TTO index and the VAS index. 4
Disease-specific QOL instruments
Disease-specific QOL instruments included were the claudication scale (CLAUS), the Kings College Vascular Quality of Life questionnaire (VASCUQOL) and sickness impact profile-intermittent claudication (SIP IC ). The CLAUS is one of the earliest diseasespecific QOL instruments for IC. It originated in Germany and has undergone several changes over time. 5, 6 Currently, it consists of 47 questions that produce a QOL health profile over five domainseveryday life (EDL), pain (P), social living (SL), illness specific fears (ISF) and psychological well-being (PW). Each domain has a maximum score of 100 (best QOL) and a minimum score of 0 (worst QOL). 7 The VASCUQOL was devised at the Kings College in London and is a disease-specific QOL instrument valid for use across the whole spectrum of patients with peripheral vascular disease i.e. claudicants and patients with critical ischaemia. It comprises of 25 questions each with seven possible responses. The total VASCUQOL score is the average score of questions answered and ranges from 1 (worst QOL) to 7 (best QOL). 8 The SIP IC was derived from the generic questionnaire sickness impact profile (SIP) that assesses sickness related behaviour. 9 It is a simple instrument that consists of 12 items and the SIP IC score is simply the total number of dysfunctional items endorsed. If none of the items are endorsed, the score Markedly worse More than one category worse or unexpected major amputation is 0 and this represents the best QOL. Conversely an SIP IC of 12 represents worst QOL. 10 Validity 'Construct' validity refers to the ability of the instrument to confirm a hypothesis i.e. patients with disease have significantly worse QOL than normal persons. A high degree of construct validity is suggested by a high correlation between QOL and clinical indicators. 'Convergent' and 'divergent' validity assess the correlation between like and non-like domains amongst different QOL instruments. 11
Responsiveness
The responsiveness of a QOL instrument can be analysed in several ways, but a widely accepted method is using 'effect sizes'. 12 Effect sizes are defined as the mean change found in a variable divided by the standard deviation of that variable. Effect sizes are used to translate the 'before and after' changes into a standard unit of measurement that should provide a clearer understanding of health status results. Effect sizes can supplement standard statistical testing to give a more complete and clinically relevant picture of health status change. 13 Effect size is the difference of the median value post and pre treatment divided by the inter-quartile range (IQR) of the pre-treatment data. An effect size O0.5 is considered clinically relevant.
Statistical analysis
Data was collected and analysed using the statistical package SPSS. Where possible, results are quoted using median and inter-quartile range (IQR). Validity of the QOL instruments was tested using Spearman rank correlation test. When testing pre and post treatment results, the Wilcoxon matched pair test was used.
Results

Clinical indicators of lower limb ischaemia
All patients completed the study and there were no dropouts. The pre-treatment median ICD was 34. 
Generic QOL instruments
According to the ISCVS outcome criteria, 48 of the 70 claudicants (69%) improved following treatment. However, only four of the eight SF36 domains significantly improved and these were the domains of physical function, bodily pain, vitality and mental health (p!0.05, Wilcoxon matched pair test). For the EUROQOL, the TTO index improved significantly after treatment from a median pre-treatment score of 0.66 to a median post-treatment score of 0.69 (pZ0.02 Wilcoxon matched pair test), but similar improvement was not seen in the VAS index (pZ0.30) (Table 3) . Although, the study mainly concentrated on the validity of disease-specific QOL instruments, there was good construct validity of the SF36 domains and the two EUROQOL indices. This was suggested by significant Spearman rank correlations between these domains and indices and ICD and MWD (Spearman rank correlation 0.219-0.576, p!0.05). Similar significant correlations were not seen between the generic domains and indices and ABPI.
Disease-specific QOL instruments
Significant improvements were seen in all three disease-specific QOL instruments after treatment.
The everyday life (EDL) domain of CLAUS improved from a median score of 52.78 pre-treatment to a median score of 61.11 post-treatment. CLAUS-pain score improved from 42.33 to 57.31. Similar significant improvements were also registered in the social life (SL), illness-specific fears (ISF) and psychological wellbeing (PW) domains of CLAUS post-treatment (p! 0.02, Wilcoxon matched pair test). The median VASCUQOL score in the 70 claudicants was 4.08, which increased to 5.16 post-treatment, a significant improvement (pZ0.01). The median SIP IC score dropped from 6 to 4 suggesting a significantly improved QOL following treatment (pZ0.05 Wilcoxon matched pair test). Table 3 shows the median QOL scores for generic and disease-specific QOL instruments pre and post treatment.
Validity
Validity was assessed using two methods i.e. construct validity and convergent-divergent validity. Significant Spearman rank order correlation between all the five domains of the CLAUS and ICD (0.267-0.677, p!0.05) and between CLAUS domains and MWD (0.295-0.697, p!0.05) suggests a high degree of 'construct' validity. Similarly, the VASCUQOL and SIP IC also showed highly significant correlation with both ICD and MWD (0.466-0.637, p!0.01) suggesting that these questionnaires also possess good construct validity. However, none of the disease-specific domains or indices tested in this study showed any correlation with the ABPI. Table 4 demonstrates the good construct validity of the CLAUS, VASCUQOL and SIP IC . Convergent and divergent validity refers to correlation between like domains of QOL instruments and, therefore, applies to QOL profiles as apposed to QOL indices.
Using the Spearman rank order correlation test, a higher correlation was seen between like domains of the CLAUS and SF36 (the two QOL profiles in this study) as apposed to non-like domains suggesting good 'convergent' and 'divergent' validity of the CLAUS (Table 5 ).
Responsiveness
Responsiveness of the QOL instruments was tested using effect sizes. An effect size greater than 0.5 is considered clinically significant. The ISCVS outcome criteria were used to stratify the results following and the VASCUQOL could detect a significant improvement in QOL in terms of effect sizes (effect size 0.5-0.74). The remaining domains and questionnaires were unable to register a clinically significant effect size O0.5 even in this group with moderate clinical improvement (Fig. 1 ).
Discussion
CMT, supervised exercise programmes (SEP), PTA and bypass surgery have all been advocated for the treatment of IC. In this study, CMT and PTA were used to treat 70 category II claudicants with reasonable success. There was a significant improvement in all clinical indicators of lower limb ischaemia i.e. walking distances and ABPI after treatment. The patients treated conservatively were given exercise advice, which could explain the overall increase in walking distances. Since, the majority of the patients were treated with angioplasty (2/3rd), there was also an overall increase in ABPI. According to ISCVS outcome criteria, six patients deteriorated. This was due to either a reduction in ABPI by 0.1 or more (three patients) or inability to complete treadmill test (three patients). Sixteen patients (23%) remained stable and the majority, 48 out of 70 patients (69%), improved after treatment. This suggests that current treatment modalities for IC are reasonably effective. The main aim of treating claudication is to reverse its detrimental effect on QOL. Overall, the QOL improved following treatment in our 70 patients. Significant improvement in QOL (p!0.05, Wilcoxon matched pair test) was seen only in four of the eight domains of the SF36 (physical function, bodily pain, vitality and mental health) and in the TTO index of the EUROQOL, but not in the VAS index. On the contrary, all domains and indices of all three disease-specific QOL instruments studied, improved significantly after treatment. This suggests that on the whole, diseasespecific QOL instruments may be more responsive than generic QOL instruments.
Construct validity is the ability of a QOL instrument to measure what it is supposed to measure. A significant Spearman rank correlation between all domains and indices of the disease-specific QOL instruments and treadmill walking distances suggests that the three instruments have good construct validity. For the CLAUS, although all five domains showed statistically significant correlation with ICD and MWD (p!0.05), the physical domains of everyday life and pain had higher spearman correlation coefficients (0.568-0.697) than the psychological domains of illness specific fears and psychological well-being (0.267-0.438). Not surprisingly, this suggests a better correlation between physical domains and treadmill walking distances as compared to psychological domains. For every disease-specific QOL domain and index the spearman correlation coefficient was greater for MWD than for ICD. For a claudicant, ICD represents pain-free walking and the difference between MWD and ICD is the painful walking that the claudicant experiences. The magnitude of this difference between ICD and MWD depends largely on the motivation and pain threshold of the patient. Our results suggest that it is MWD that is more important for the claudicant and reduction in MWD has a more adverse impact on the claudicants' QOL.
There was no correlation between ABPI and disease-specific QOL domains or indices. This suggests that walking ability is more important for the claudicant than total lower limb blood flow and a reduction in walking ability has a much greater impact on the claudicants' QOL than a reduction in ABPI. This also means that a lower ABPI does not equate with poorer QOL and this factor alone should not be used to plan or prioritise treatment in IC. The validity of generic questionnaires has been established in IC 8 and this study aim to evaluate the validity of diseasespecific QOL instruments. However, our results show that overall, the Spearman rank correlation coefficients between disease-specific domains/indices and walking distances (0.267-0.697) was higher than the correlation coefficients between generic domains/ indices and walking distances (0.219-0.576). This suggests a better construct validity of the diseasespecific QOL instruments as compared with generic QOL instruments.
The advantage of disease-specific QOL instruments over generic QOL instruments is their greater responsiveness. This responsiveness should be equally sensitive to improvement and deterioration in the patients' condition. However, none of the QOL instruments studied here could detect mild deterioration in the patients' clinical condition in terms of significant deterioration in QOL. Using effect sizes as a measure of responsiveness, a significant deterioration in QOL should register an effect size of K0.5. This was not seen in any of the QOL instruments studied. One reason for this could be a type II error or small numbers, as only six patients had mild deterioration (ISCVS outcome K1) following treatment. Another reason often cited for poor responsiveness of QOL instruments to deterioration is a 'floor effect' i.e. patients initially score the lowest possible score so further deterioration cannot be registered. This is unlikely to be the case here because this study involved claudicants, who unlike patients with critical ischaemia are not clinically on the lowest rung of the peripheral arterial disease ladder.
Sixteen claudicants in the study remained stable with no change in their clinical condition following treatment (ISCVS outcome 0). There was no significant change in QOL in these patients as the effect size did not reach the significant level of 0.5 for any of the domains or indices. This is important because it implies that there is no placebo effect associated with QOL analysis.
Thirty-four claudicants had mild improvement following treatment (ISCVS outcome C1). However, only the pain domain of CLAUS and VASCUQOL could detect this improvement in terms of significant improvement in QOL. The stratification of clinical outcome following treatment into mild, moderate and marked as described by the ISCVS is based on a combination of completion of treadmill walking test and/or increase in ABPI and a reasonably responsive QOL instrument should be able to detect improvement in QOL in these three broad outcome categories preferably in a step-wise fashion.
Fourteen claudicants had moderate improvement following treatment (ISCVS outcome C2). Only two domains of CLAUS (pain and everyday life) and VASCUQOL demonstrated significant improvement in QOL in these patients. For the CLAUS this seems disappointing, being a disease-specific QOL instrument specifically designed for IC, one may expect significant QOL improvements in all its five domains in this group of moderate clinical improvement. Three of the eight domains of SF36 were able to detect moderate clinical improvement in terms of significant improvement in QOL. In terms of responsiveness, the SF36 appears to be equivalent to the CLAUS. The SF36 is the established generic QOL instrument for IC, but the extra time, effort and resources involved in administering the CLAUS along with the SF36 could be questioned.
In conclusion, validity, both construct and convergent-divergent validity is acceptable for all three disease-specific QOL instruments tested. The VASCU-QOL was the only instrument that could detect both mild and moderate clinical improvement and thus offers advantages over generic QOL indices. We, therefore, recommend, based on responsiveness, the VASCUQOL is the only disease-specific QOL instrument that merits routine use in claudicants. The SF36 is the established leader amongst generic QOL instruments. Therefore, future researchers and clinicians analysing QOL in claudicants should include the generic questionnaire SF36 and the disease-specific questionnaire VASCUQOL.
